Inclusion Criteria:  Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted Have adequate organ function ECOG PS 0-1  Dose Escalation:  Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO Any solid tumor with EGFR and / or HER2 aberration  Dose Expansion:  Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma) Cohort A: Non-small cell lung cancer (NSCLC) Cohort B: HER2 positive breast cancer Cohort C: Recurrent or refractory glioblastoma Cohort D: Other solid tumors with EGFR or HER2 aberrations  Exclusion Criteria:  Non-stable brain metastases Have significant cardiovascular disorder Have not recovered from prior cancer treatment A serious illness or medical condition